• Publications
  • Influence
Safety and immunogenicity of an investigational quadrivalent meningococcal CRM(197) conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America.
BACKGROUND This study compared the investigational quadrivalent meningococcal CRM₁₉₇ conjugate vaccine, MenACWY-CRM, with licensed quadrivalent polysaccharide (MPSV4) and conjugate (MenACWY-D)Expand
  • 39
  • 3
Immunogenicity and safety of a quadrivalent meningococcal polysaccharide CRM conjugate vaccine in infants and toddlers.
OBJECTIVES This phase III study assessed the safety and immunogenicity of MenACWY-CRM, a quadrivalent meningococcal conjugate vaccine, administered with routine vaccines starting at 2 months of age.Expand
  • 24
  • 3
Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone and netilmicin for 14 days: a prospective multicenter study.
A 2-week course of ceftriaxone (2 g) plus netilmicin (4 mg/kg), administered as one short daily iv infusion, was evaluated for the treatment of streptococcal endocarditis in an open multicenterExpand
  • 129
  • 2
Antibiotic management of outpatients with endocarditis due to penicillin-susceptible streptococci.
Thirty patients with endocarditis caused by penicillin-susceptible streptococci were enrolled in one of two groups in this study. Fifteen patients received ceftriaxone (2 g once daily) for 4 weeks;Expand
  • 90
  • 2
First report of vancomycin-resistant Enterococcus faecium isolated in Argentina.
  • 37
  • 2
Indications of a new antibiotic in clinical practice: results of the tigecycline initial use registry.
Tigecycline is the first of a new class of antibiotics named glycylcyclines and it was approved for the treatment of complicated intra-abdominal infections and complicated skin and skin structureExpand
  • 29
  • 2
  • PDF
Risk factors for mortality in burn children.
UNLABELLED Studies about risk factors for mortality in burn children are scarce. We conducted this study to evaluate the risk factors for mortality in pediatric burn patients. We included 110Expand
  • 20
  • 2
  • PDF
Acceptance of Intanza® 9 μg intradermal influenza vaccine in routine clinical practice in Australia and Argentina
IntroductionIntanza® 9 μg (Sanofi Pasteur SA, Lyon, France), a split virion trivalent influenza vaccine delivered by intradermal injection with a microinjection system, became available as aExpand
  • 36
  • 1
A cost-benefit analysis of programmatic use of CVD 103-HgR live oral cholera vaccine in a high-risk population.
BACKGROUND Cholera spread to Latin America in 1991; subsequently, cholera vaccination was considered as an interim intervention until long-term solutions involving improved water supplies andExpand
  • 28
  • 1
  • PDF
Outpatient treatment of infective endocarditis.
Studies from Europe and the USA have shown that infective endocarditis (IE) has an incidence of 2-4 per 100 000 person years in the general population. In the USA, the direct medical costs involvedExpand
  • 11
  • 1